The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Bal Pharma Ltd

Bal Pharma Ltd

BSE 524824 · NSE BALPHARMA · ISIN INE083D01012 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹84.49

+1.28%

BSE close, 28 August 2026

Market cap

₹134.52 cr

1.6 cr shares · Micro cap

Free float

₹64.90 cr

as published

P/E · P/B

17.7× · 1.26×

EPS ₹4.77 · BV ₹67.06

FY25-26 rev / PAT

310.80 / 6.75

₹ cr, as filed

Filings, window

21

3 selected · 14%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹59.69 52-WK HIGH ₹99.00 ₹84.49 63% of range
Against 52-week high-14.7%
Against 52-week low+41.5%
Day change+1.28%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹4.77
Price / earnings17.71×
Price / book1.26×
Book value — derived, price ÷ P/B₹67.06
Return on equity7.11%
Operating margin9.51%
Net margin1.31%

Consistency check

P/B ÷ P/E, which must equal ROE
7.11%
ROE as published
7.11%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 88.43 1.16 0.73 9.51% 1.31%
Mar-26 · Q 83.92 3.70 2.60 12.40% 4.41%
FY25-26 310.80 6.75 4.27 11.01% 2.17%

Quarter on quarter

Revenue, quarter on quarter
+5.4%
Net profit, quarter on quarter
-68.6%
Operating margin, quarter on quarter
-289 bps

Disclosure profile 21 filings in the window

0 median 17.0 p75 · 25 sector max 52 21 64th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

21 filings · 3 selected · busiest 2026-08-26 and 2026-09-25

Filing rhythm · the twelve most recent

2026-08-262026-10-07

SelectedProcedural

Filings

21 in the window · 4 earlier on record

  1. 7 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Reg 74 (5) of SEBI (DP) Regulation 2018 for the quarter ended 30th September 2026

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 25 September 2026 ·

    Change in Directorate

    Change in Directorate

    Change in Designation of Directors and Reconstitution of Statutory Committee with effective from 01st October 2026 as approved members at 39th AGM of Company held on 24th September 2026 ....

    Company Update / Change in Directorate View filing →

  3. 25 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Enclosed Voting Result and Scrutinizers Report of 39th AGM held on 24th September 2026

    AGM/EGM / AGM View filing →

  4. 25 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of Closure of Trading Window from 01st October 2026 till 48 hours after the declaration of the financial result of the Company for the quarter ended 30th September 2026 (Q2)

    Insider Trading / SAST / Closure of Trading Window View filing →

  5. 24 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Enclosed Proceedings of the AGM of Bal Pharma Limited held on 24th September 2026

    AGM/EGM / AGM View filing →

  6. 10 September 2026 ·

    General

    Clarification Regarding Movement In Price

    Clarification regarding Movement in Price asper attachment

    Company Update / General View filing →

  7. 10 September 2026 ·

    Clarification

    Clarification sought from Bal Pharma Ltd

    The Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....

    Company Update / Clarification

  8. 7 September 2026 ·

    Allotment

    Allotment

    Confirming the Allotment of Convertible Warrants on Preferential basis

    Company Update / Allotment of Equity Shares View filing →

  9. 27 August 2026 ·

    Record Date

    Intimation Of Record Date For Final Dividend

    In Continuation of Previous intimation hereby informing 17th September 2026 fixed as Record date for payment of final dividend and communication to shareholders regarding TDS on dividend payment

    Corp. Action / Record Date View filing →

  10. 26 August 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Bal Pharma Limited Annual Report 2026

    Others / Reg. 34 (1) Annual Report View filing →

  11. 26 August 2026 ·

    AGM / EGM

    Bal Pharma Limited - Notice Of AGM

    39th AGM of the Company Scheduled on 24th September 2026. Notice copy enclosed

    AGM/EGM / AGM View filing →

  12. 26 August 2026 ·

    AGM / EGM

    Intimation - 39Th AGM Scheduled On 24Th September 2026

    This is to inform that 39th AGM of Bal Pharma Limited Scheduled to be held on Thursday 24th September 2026 at 11.00 AM through VC Mode.

    AGM/EGM / AGM View filing →

  13. 25 August 2026 ·

    General

    Clarification With Respect To Tentative Timeline For Utilization Of Net Proceeds Of Preferential Issue

    This is in Continuation of Company earlier intimation made in connection with allotment of warrants , hereby clarify that utilization of net proceeds or tenure of warrants is 18 month from ....

    Company Update / General View filing →

  14. 13 August 2026 ·

    General

    Newspaper Publications - Unaudited Financial Results 30Th June 2026 And IEPF Notice

    In Continuation of Outcome of Board meeting dated August 12 2026 , Published Unaudited Financial result for the quarter ended 30th June 2026 and IEPF Notice in Financial express and Sanjevani ....

    Company Update / General View filing →

  15. 12 August 2026 ·

    Results

    Financial Result For The Quarter End 30Th June 2026

    Enclosed Financial Result for the First quarter ended 30th June 2026 together with Limited Review Report as submitted by Statutory auditor

    Result / Financial Results View filing →

  16. 12 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, August 12 2026

    Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone ....

    Board Meeting / Outcome of Board Meeting View filing →

  17. 10 August 2026 ·

    Postal Ballot

    Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    Scrutinizers Report Pertaining to Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23rd 2026.

    AGM/EGM / Postal Ballot View filing →

  18. 10 August 2026 ·

    Postal Ballot

    Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    Outcome : Result of Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23 , 2026

    AGM/EGM / Postal Ballot View filing →

  19. 5 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Statements Of The Company For The First Quarter Ended 30Th June 2026 And Other General Business Matters

    Bal Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....

    Board Meeting / Board Meeting View filing →

  20. 30 July 2026 ·

    General

    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 : Intimation Regarding Notice Of Postal Ballot

    Company Providing opportunity to shareholders to Submit their Comments on Corrigendum to the Postal ballot notice

    Company Update / General View filing →

  21. 23 July 2026 ·

    General

    Intimation Regarding Corrigendum To The Postal Ballot Notice

    In Continuation of Postal Ballot Notice dated 09th July 2026 , Submitting Corrigendum as integral part to the Said Notice.

    Company Update / General View filing →

RSS feed for Bal Pharma Ltd · the 50 most recent filings